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Crohn\'s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. Although mild disease can be treated with 5-aminosalicylates (5-ASAs), many patients eventually require corticosteroids for symptom control \[[@B1]\]. Tumor necrosis factor a (TNF-α) is a proinflammatory cytokine that plays an important role in CD pathogenesis \[[@B2],[@B3],[@B4]\]. Infliximab, a chimeric monoclonal antibody directed against TNF-α that neutralizes its biological activity \[[@B5]\], was the first biological therapy to be approved for CD and has become an important tool in the treatment of this disease.

Infliximab has been recommended by different organizations for induction therapy and maintenance therapy of CD. The definitive indications for induction therapy with infliximab are: (1) moderate to severe inflammatory CD with an inadequate response to conventional therapy (defined by severity of symptoms and/or lack of response to standard therapy such as corticosteroids, azathioprine, 6-mercaptopurine, and methotrexate); (2) fistulizing CD with draining cutaneous or perianal fistulas.

The definitive indications for maintenance therapy with infliximab are: (1) inflammatory or fistulizing CD that responded to initial induction therapy with infliximab and failed maintenance therapy with one or more immunosuppressive agents; (2) corticosteroid-treated CD that failed an attempt at corticosteroid sparing with one or more immunosuppressive agents \[[@B6]\]. Other potential uses of infliximab in different CD settings are currently under investigation. We have used infliximab in CD patients previously controlled by immunosuppressive agents who presented with perirectal bleeding. Herein we report the effects of infliximab on gastrointestinal bleeding in CD. This is the first report of evaluation of small bowel CD lesions before and after administration of infliximab using double-balloon endoscopy.

Case Reports {#sec1_2}
============

Case 1 was an 18-year-old male who was admitted to our hospital after complaining of melena for 1 day. He had a 2-year history of CD. His serum C-reactive protein (CRP) level was 2.7 mg. Colonoscopy showed a linear ulcer in the descending colon with no evidence of bleeding. A few aphthous ulcers were observed in the transverse colon and terminal ileum with no signs of bleeding. Double-balloon endoscopy revealed one large ulcer and several irregularly shaped ulcers in the terminal ileum ([fig. 1](#F1){ref-type="fig"}a). The patient was given a single intravenous 5 mg/kg dose of infliximab. Eight weeks after infliximab administration, double-balloon endoscopy revealed a reduction in size and complete healing of the lesions ([fig. 1](#F1){ref-type="fig"}b). The patient has been receiving infliximab maintenance therapy at a dose of 5 mg/kg every 8 weeks. He is currently symptom-free with no evidence of disease relapse.

Case 2 was a 21-year-old female who was admitted to our hospital after complaining of melena for 2 days. She had a 5-year history of CD. Her serum CRP level was 4.6 mg/dl. Double-balloon endoscopy showed linear ulcers in the jejunum with ulcer scars. The ileum also showed ulcer scars with mucosal edema. The patient was given intravenous infliximab 5 mg/kg. Five weeks after infliximab administration, double-balloon endoscopy showed that all lesions were decreased in size and were healed. The patient has been receiving infliximab maintenance therapy every 8 weeks. She is currently symptom-free.

Case 3 was a 31-year-old female who visited our hospital with mild abdominal pain without melena. On physical examination she was found to be anemic (hemoglobin level 5.9 g/dl) and her serum CRP was 1.0 mg/dl. The patient had a 2-year history of CD. Colonoscopy showed aphthous ulcers in the colon. Subsequently, double-balloon endoscopy revealed ulcerations and stenosis in the terminal ileum ([fig. 2](#F2){ref-type="fig"}a). The patient was given infliximab 5 mg/kg. Twelve weeks after infliximab administration, double-balloon endoscopy showed ulcer healing and an increased diameter of the ileal stenosis ([fig. 2](#F2){ref-type="fig"}b). The patient has been receiving infliximab maintenance therapy. She is currently symptom-free and her anemia is improving.

Discussion {#sec1_3}
==========

Acute lower gastrointestinal hemorrhage in an unusual complication of CD that occurs in 0.9-6% of cases \[[@B7],[@B8],[@B9]\]. Localization of the disease site remains a major challenge. Double-balloon endoscopy has been useful for identifying the bleeding site and also for excluding non-CD-related perirectal bleeding. Both medical and surgical modalities are used to manage lower gastrointestinal bleeding due to CD. Traditionally, medical treatment of CD primarily consisted of 5-ASAs and corticosteroids, with other, nonsurgical therapies including endoscopic treatment and interventional angiography. However, the outcomes or these therapies are not satisfactory, and 60-91% of cases require surgery \[[@B8]\]. Furthermore, up to 35% of medically treated patients experience recurrent bleeding episodes \[[@B7]\]. Although rebleeding is negligible in patients who undergo primary excisional surgery, such surgery is associated with various hazardous complications.

The anti-TNF-α antibody infliximab has been shown to induce rapid mucosal healing \[[@B10],[@B11]\]. Infliximab treatment of severe, recurrent CD presenting as massive lower gastrointestinal bleeding has been shown to result in rapid mucosal healing and to prevent recurrent bleeding \[[@B12],[@B13]\], suggesting that infliximab may offer a viable treatment alternative to surgery for patients with acute massive or chronic refractory bleeding \[[@B14]\]. Furthermore, infliximab could potentially modify the expected time course of the disease in a relevant number of patients by stopping further development of, or causing regression of, stenotic lesions, thereby postponing or avoiding surgical interventions \[[@B15]\]. In our series, all three patients promptly responded to infliximab therapy, as their gastrointestinal bleeding stopped after a single dose and stenosis also improved. Furthermore, these patients have also received continual maintenance therapy with no evidence of disease relapse. It therefore seems feasible that infliximab may be useful in treating CD relapse characterized by gastrointestinal bleeding in patients who previously received other therapies.

In conclusion, we have reported that all of our patients promptly responded to infliximab therapy, manifested as halting of gastrointestinal bleeding. This is the first report to show double-balloon endoscopic findings before and after administration of infliximab, which appears to be useful for stopping gastrointestinal bleeding and thereby preventing the need for surgery in CD patients.

![**a** Double-balloon endoscopy showed a large ulcer and several irregularly shaped ulcers in the terminal ileum. **b** Double-balloon endoscopy showed a reduction in size and complete healing of the lesions in the terminal ileum 8 weeks after infliximab treatment.](crg0003-0193-f01){#F1}

![**a** Double-balloon endoscopy revealed ulcerations and stenosis in the terminal ileum. **b** Double-balloon endoscopy showed ulcer healing and an increased diameter of the ileal stenosis 12 weeks after infliximab treatment.](crg0003-0193-f02){#F2}
